Actions | Visit 0 Screening | Visit 1 Inclusion | Visits 2–8 Follow-up | Visit 9 End of trial |
---|---|---|---|---|
Written informed consent | X | |||
Web-based randomization | X | |||
Demographic details | X | X | ||
Medical history | X | X | X | X |
Physical examination | X | X | X | X |
Investigator Global Assessment | X | X | X | X |
Eczema Area and Severity Index, Severity of Atopic Dermatitis Index | X | X | X | |
Quality of Life: Dermatology Life Quality Index | X | X | X | |
Patient-Oriented Severity of Atopic Dermatitis Index, Patient-Oriented Eczema Measure | X | X | Computer record every 4 weeks | X |
Estimation of solar exposure | X | X | X | |
Complete blood count, serum chemistry, serum creatinine, serum calcium and phosphate, serum parathyroid level | X | X | ||
Serum total IgE level | X | X | X | |
Vitamin D dosage | X | X | X | |
Delivery of oral vitamin D or placebo vial | X | X | ||
Checking for adverse events | X | X |